Beam Therapeutics Inc.
BEAM · Nasdaq · United States
Share price · BEAM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BEAM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Oct 2026+15.6%
- 8 Sep 2026-9.5%
- 25 Aug 2026+9.5%
Nothing announced by BEAM that day or the session before.
- 4 Aug 2026+9.4%
- 23 Jun 2026-6.6%
Nothing announced by BEAM that day or the session before.
- 4 Jun 2026+11.1%
Nothing announced by BEAM that day or the session before.
- 6 May 2026+11.9%
Nothing announced by BEAM that day or the session before.
- 27 Apr 2026+7.6%
Nothing announced by BEAM that day or the session before.
- 24 Apr 2026-10.1%
Nothing announced by BEAM that day or the session before.
- 13 Apr 2026+10.0%
Nothing announced by BEAM that day or the session before.
Share of unusual movement by asset
For each asset, the share of BEAM's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Ristoglogene autogetemcelevents and moves
| 1 | shown from 8 days |
BEAM-302events and moves
| 1 | shown from 8 days |
BEAM-301events and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 7% |
| Other company news (earnings, financing, releases naming no asset) | — | 21% |
| Sessions with no dated event | — | 72% |
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | G6PC1 (glucose-6-phosphatase-alpha) R83C variantGene therapy / editing | Glycogen Storage Disease Type Ia | |
| Phase 1/2 | SERPINA1 PiZ mutation (E342K)Gene therapy / editing | Alpha-1 Antitrypsin Deficiency | |
| Phase 1/2 | HBG1/HBG2 promotersGene therapy / editing | Sickle Cell Disease | |
| Preclinical / Unstaged | PAH gene (phenylalanine hydroxylase)Gene therapy / editing | Phenylketonuria |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2028 (2)
February 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.3M | $110M | $220M+ $831M short-term inv. | $134M-$111M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.5M | $95M | $227M+ $933M short-term inv. | $123M-$66M operating cash flow | report ↗ |
| 2026-Q1 | $32M | $105M | $295M+ $923M short-term inv. | $94M-$129M operating cash flow | report ↗ |
| 2025-Q3 | $9.7M | $110M | $275M+ $807M short-term inv. | $113M-$81M operating cash flow | report ↗ |
| 2025-Q2 | $8.5M | $102M | $289M+ $868M short-term inv. | $102M-$76M operating cash flow | report ↗ |
| 2025-Q1 | $7.5M | $99M | $535M+ $692M short-term inv. | $109M-$104M operating cash flow | report ↗ |
| 2024-Q3 | $14M | $94M | $237M+ $696M short-term inv. | $97M-$88M operating cash flow | report ↗ |
| 2024-Q2 | $12M | $87M | $299M+ $715M short-term inv. | $91M-$83M operating cash flow | report ↗ |
| 2024-Q1 | $7.4M | $85M | $294M+ $807M short-term inv. | $99M-$100M operating cash flow | report ↗ |
| 2023-Q3 | $17M | $100M | $178M+ $846M short-term inv. | $96M-$90M operating cash flow | report ↗ |
| 2023-Q2 | $20M | $98M | $241M+ $847M short-term inv. | $83M-$85M operating cash flow | report ↗ |
| 2023-Q1 | $24M | $100M | $260M+ $810M short-term inv. | $96M-$110M operating cash flow | report ↗ |
| 2022-Q3 | $16M | $85M | $169M+ $943M short-term inv. | $110M-$75M operating cash flow | report ↗ |
| 2022-Q2 | $17M | $75M | $278M+ $934M short-term inv. | $72M-$52M operating cash flow | report ↗ |
| 2022-Q1 | $8.4M | $65M | $310M+ $903M short-term inv. | $69M$218M operating cash flow | report ↗ |
| 2021-Q3 | $0.8M | $55M | $627M+ $321M short-term inv. | $28M$3.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $140M | $410M | $302M+ $950M short-term inv. | $20M-$345M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $64M | $368M | $290M+ $569M short-term inv. | $94M-$347M operating cash flow | report ↗ |
| 2023-FY | $378M | $437M | $445M+ $754M short-term inv. | $33M-$149M operating cash flow | report ↗ |
| 2022-FY | $61M | $312M | $246M+ $845M short-term inv. | $72M$23M operating cash flow | report ↗ |
| 2021-FY | $52M | $387M | $573M+ $406M short-term inv. | $93M-$66M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 31 sales ($19.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2033-06-06 | Walsh Kathleen E · director | Award / grant (derivative) | 16,532 | — | — | Form 4 |
| 2026-10-16 | Evans John M. · director, CEO | Option exercise | 25,000 | $1.03 | $26K | Form 4 |
| 2026-10-16 | Evans John M. · director, CEO | Open-market sale | 25,000 | $23.98 | $600K | Form 4 |
| 2026-10-16 | Evans John M. · director, CEO | Option exercise (derivative) | 25,000 | — | — | Form 4 |
| 2026-10-15 | Evans John M. · director, CEO | Option exercise | 25,000 | $1.03 | $26K | Form 4 |
| 2026-10-15 | Evans John M. · director, CEO | Open-market sale | 25,000 | $23.57 | $589K | Form 4 |
| 2026-10-15 | Evans John M. · director, CEO | Option exercise (derivative) | 25,000 | — | — | Form 4 |
| 2026-10-01 | Cavanagh Bethany J · SVP, Finance and Treasurer | Open-market sale | 187 | $24.41 | $5K | Form 4 |